MedTrace Logo

TNF-Alpha Inhibition for Treatment of Alzheimer's Disease

NCT00203320 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2006-04-24

No results posted yet for this study

Summary

It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.

Conditions

Interventions

DRUG

etanercept given by perispinal administration

Sponsors & Collaborators

  • Tobinick, Edward Lewis, M.D.

    lead OTHER

Principal Investigators

  • Edward L. Tobinick, M.D. · unaffiliated (Assistant Clinical Professor of Medicine, David Geffen School of Medicine at UCLA)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Completion
2006-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00203320 on ClinicalTrials.gov